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Abstract:  Glucose  homeostasis  is  a  fundamental  aspect  of  life  and  its  dysregulation  is 
associated  with  important  diseases,  such  as  cancer  and  diabetes.  Traditionally,  glucose 
radioisotopes  have  been  used  to  monitor  glucose  utilization  in  biological  systems. 
Fluorescent-tagged glucose analogues were initially developed in the 1980s, but it is only in 
the past decade that their use as a glucose sensor has increased significantly. These analogues 
were developed for monitoring glucose uptake in blood cells, but their recent applications 
include tracking glucose uptake by tumor cells and imaging brain cell metabolism. This 
review outlines the development of fluorescent-tagged glucose analogues, describes their recent 
structural modifications and discusses their increasingly diverse biological applications.  
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1. Introduction 
1.1. Why is Measuring Glucose Utilization so Important?  
Glucose (C6H12O6, also known as D-glucose, dextrose, or grape sugar) is a monosaccharide and a 
pivotal  carbohydrate  in  biology  [1,2].  The  ability  to  effectively  monitor  glucose  homeostasis  is 
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crucially important in many aspects of biological research and medicine. This is because glucose is the 
primary source of energy in organisms and an important metabolic intermediate [1,2]. For example, 
glucose is a major product of photosynthesis and the starting point for cellular respiration. Moreover, 
high  blood  glucose  levels  in  diabetes  is  a  precursor  of  diabetes-associated  side  effects,  such  as 
blindness, atherosclerosis and neuropathy [3,4]. There is also a major need for measuring glucose flux 
in  neuroscience.  In  the  brain,  glucose  oxidation  is  believed  to  support  almost  all  of  the  energy 
requirements of neuronal cells, via conversion to lactate by associated astrocyte cells [5]. Glucose flux 
is tightly linked to neuronal responses and, hence, brain activity. This has been a major reason for 
developing fluorescent-tagged glucose bioprobes to monitor rapid changes in glucose flux in brain 
tissue [5]. Contemporary research in this area has focused on defining the astrocyte-neuron metabolic 
relationships  governing  brain  homeostasis  and  memory  formation  [6,7].  A  further,  very  important 
reason to measure glucose flux is related to the altered metabolism of cancer cells compared to healthy 
cells  [8].  This  is  known  as  the  Warburg  effect  and  was  postulated  in  the  1920s  by  the  German 
biochemist, Otto Warburg [9]. The rapidly proliferating cancer cells have glycolytic rates that can be 
up to 200 times greater than equivalent cells from their normal tissues of origin [10]. Consequently, 
glucose consumption is markedly increased in cancer cells and, interestingly, occurs even if oxygen is 
relatively  plentiful.  Therefore,  tracking  glucose  uptake  can  delineate  cancer  from  normal  tissues, 
providing a means to image cancer progression and monitor response to therapeutics. 
It is interesting to speculate about why glucose is the prominent fuel instead of other monosaccharides, 
such as fructose or galactose. One reason may be the relatively high stability of glucose compared to 
other monosaccharides [1]. In their open chain form, monosaccharides contain carbonyl groups that 
react with the amino groups of proteins to form Schiff bases, which rearrange into a relatively stable 
amino-ketone linkage that compromises protein function. However, the hydroxyl groups of the glucose 
ring are equatorial, which contributes to its relatively high stability. It should be noted, however, that 
glycation still occurs and is linked to complications arising from diabetes [11]. The role of glucose  
is  also  of  biological  importance  in  this  context,  because,  the  addition  of  glucose  to  proteins  by  
enzyme-mediated glycosylation is often essential for their function [1]. 
1.2. Monitoring Glucose Utilization before the Development of Fluorescent-Tagged Glucose Bioprobes 
Prior  to  the  invention  of  fluorescent-tagged  glucose  bioprobes,  radioisotopically-labeled  sugars 
were  widely  used  for  measuring  glucose  utilization  (i.e.,  see  [12–16]).  These  radiolabeled  tracers 
include [
14C] 2-deoxy-D-glucose [13], [
18F] fluoro-2-deoxy-D-glucose (FDG; [17]), and [
14C] or [
3H]3-
Omethyl-D-glucose [18,19]. It should be noted that FDG still remains an essential non-invasive tool 
for  monitoring  glucose  utilization  and  FDG-PET  is  routinely  used  for  brain  mapping  or  cancer 
diagnosis and staging (i.e., see [20–28]). Apart from the technical and logistical problems associated 
with radioactivity, these tracers cannot measure glucose uptake in viable, living cell cultures, i.e., the 
cells  have  to  be  killed  for  measurement  and  individual  cells  in  a  diverse  population  cannot  be 
monitored. In addition, 6-NBDG has been used to measure glial cell glucose transport in real-time 
using confocal microscopy cells [29]. Time resolution was an important consideration in this study 
because fluorescent techniques can resolve cellular events within seconds, whereas isotopic techniques 
can only resolve within minutes. This is a critical issue for cells that change their metabolic status very Sensors 2012, 12  5007 
 
 
rapidly,  which  occurs  in  brain  tissue.  Subsequent  glucose  utilization  studies  using  6-NBDG  and  
2-NBDG compared co-cultures of glial cells and neurons [30] and cerebellar slices [31], which are also 
not possible with glucose isotopes. Thus, fluorescent analogues are superior to isotope analogues in 
terms of temporal resolution and spatial resolution. Thus, autoradiography using isotopes measure 
cellular phenomena in real-time; the only time point possible for analysis is not compatible with cell 
physiology and, therefore, should be considered as an ex vivo parameter. Moreover, the limits of two-
photon extracellular polar-tracer (TEP), which can be used to image long-term changes in neural or 
glial cells in a living tissue [32,33], are a poor temporal resolution and poor spatial resolution in the 
millimetre range. This means that cellular phenomena can remain unresolved. An alternative method 
was also available for cellular studies; glucose utilization could also be monitored by light scattering 
effects in red blood cells, caused by volume changes after sugar transfer [34]. In addition, a volumetric 
method  to  estimate  glucose  transport  has  been  utilized  in  tumor  cells  [35]  and  brain  cells  [29]. 
However, this method is an indirect measure of glucose transport and that changes in cell volume may 
affect glucose metabolism via the activation of volume-regulatory cellular mechanisms. 
Therefore,  the  development  of  a  fluorescent  glucose  bioprobe  would  have  been  advantageous, 
because fluorescence spectroscopy can provide a relatively sensitive platform for monitoring glucose 
transport [34]. This would also allow the evaluation of cell viability, which could be readily analyzed 
by coupling with an image analyzing system [36]. In addition, at this time there was no method to 
measure  both  glucose  transport  and  its  effect  on  different  intracellular  functions  in  single,  viable 
mammalian cells or tissues. 
Figure 1. Timeline to show that research aimed at the development of fluorescent-tagged 
glucose bioprobes is increasing. Each new published probe is shown as a yellow box. 
Please refer to the relevant section of this review for a detailed explanation of each probe. 
 
The  development  of  fluorescent-tagged  glucose  bioprobes  began  in  the  1980s  [34].  However, 
advances in this field of research were relatively slow and it would be another 10 years before an 
alternative fluorescent-tagged probe would be developed, which became more widely used by the 
biological research community [37,38]. This spurred research in this field and in the past decade we 
have witnessed the development of a large number of fluorescent-tagged glucose bioprobes. These 
advances are shown schematically in Figure 1. Therefore, it is an appropriate time to review these 
advances and attempt to place them into a relevant research context, by comparing the experimental 
„strengths‟ and „weaknesses‟ of each probe. Sensors 2012, 12  5008 
 
 
2. The First Generation of Fluorescent-Tagged Glucose Bioprobes 
Ideally, fluorescent tagged glucose bioprobes should possess a number of characteristics that will 
make them suitable as glucose analogues. These features should include a suitable molecular weight 
compared to glucose, low cytotoxicity, competition by glucose for cellular uptake and resistance to 
quenching or photo-bleaching (for further information, see [39]). In addition, the ability of the probe to 
be metabolized by the cell should also be considered (this aspect is addressed in the description of  
2-NBDG and 6-NBDG, below).  
2.1. Development of 6-NBDG  
The first fluorescent-tagged glucose bioprobe was developed in 1985 [34]. The probe is 6-deoxy-N-
(7-nitrobenz-2-oxa-l,3-diazol-4-yl)-aminoglucose (6-NBDG; Figure 2(A)) and it was synthesized by 
Professor Howard Kutchai‟s laboratory in the University of Virginia, in conjunction with the company 
Molecular  Probes  Inc.  At  that  time,  only  one  fluorescent  glucose  analogue  had  been  developed:  
2-deoxy-2-amino-N-(5-dimethylamino-1-naphthalene sulfonyl)-glucose (III). However, this analogue 
had only been used as a competitive inhibitor of hexokinase [40]. 6-NBDG was the first fluorescent 
glucose derivative developed to probe the behavior of glucose transport systems. In designing this 
fluorescent analogue, the fluorophore 7-nitrobenz-2-oxa-l,3-diazol-4-yl (NBD) was selected because 
of its relatively strong fluorescence [34]. The C-6 position of D-glucose was selected as the site for 
covalent attachment, because it was thought that the hydrophobic region of the hexose transporter is in 
close proximity to this part of the glucose molecule during transport into the cell [41]. 
Figure  2.  (A)  Chemical  structure  of  6-deoxy-N-(7-nitrobenz-2-oxa-l,3-diazol-4-yl)-
aminoglucose(6-NBDG),  developed  in  1985;  (B)  Chemical  structure  of  2-deoxy-N-(7-
nitrobenz-2-oxa-l,3-diazol-4-yl)-aminoglucose(2-NBDG), developed in 1996. Both probes 
are commercially available from Invitrogen, Corp. 
   
(A)     (B) 
Professor Kutchai and his colleagues tested 6-NBDG in red blood cells. Importantly, it was shown 
that 6-NBDG entry into the cells was inhibited by increasing concentrations of D-glucose [34]. This 
indicated  that  6-NBDG  entered  the  cell  through  glucose  transporters  (GLUTs).  This  was  further 
validated by showing that entry was inhibited by cytochalasin B, which is a mycotoxin and a high 
affinity GLUT inhibitor that disrupts actin polymerization [42,43]. Sensors 2012, 12  5009 
 
 
However, it was also observed that the entry rate for 6-NBDG is much slower compared to other 
monosaccharides. The authors speculated that this could be due to 6-NBDG having a low affinity for 
GLUT, or the maximal uptake (Vmax) for 6-NBDG uptake is much lower than glucose [34]. This point 
would be further addressed in an important study by Barros et al. in 2009 ([44] and discussed in 
Section 2.2). 
Although  6-NBDG  was  made  available  by  Molecular  Probes,  Inc.,  which  was  subsequently 
assimilated  by  Invitrogen,  Corp.,  its  use  by  the  biological  research  community  was  quite  sparse, 
because in the subsequent nine years there were only four published studies that used 6-NBDG to 
monitor  glucose  transport.  These  reports  included  assessment  of  the  effects  of  phorbol  esters  on 
glucose uptake and regional differences in glucose transport in the mouse hippocampus [45]. In addition, 
two photon microscopy has been used to image 6-NBDG uptake in rat brain tissue in vivo [46]. In this 
study, astrocytes and neurons both take up 6-NBDG at the same rate in the barrel cortex of the rat 
brain.  However, during intense neuronal  activity triggered by whisker stimulation, rapid  6-NBDG 
uptake by astrocytes could be observed, whereas neuronal uptake remained almost unchanged. This 
latter study was important, because it demonstrated that a fluorescent-tagged glucose bioprobe could 
be used to monitor glucose uptake in vivo. 
2.2. Development of 2-NBDG  
Eleven  years  after  the  development  of  6-NBDG,  Hideaki  Matsuoka‟s  Laboratory,  at  
Tokyo University of Agriculture and Technology, synthesized 2-(N-(7-nitrobenz-2-oxa-l,3-diazol-4-
yl)amino)-2-deoxyglucose (2-NBDG; Figure 2(B)) [37]. Matsuoka‟s Research Group was interested in 
monitoring bacteria viability and metabolic events. The probe 6-NBDG could not be used to directly 
monitor  cell  metabolism,  because  the  modification  at  the  C-6  position  of  glucose  would  inhibit 
phosphorylation by the glycolytic enzyme, hexokinase, leading to 6-NBDG accumulation within the 
cells. However, NBD modification at the C-2 position of glucose, to generate 2-NBDG, would allow 
phosphorylation by hexokinase and subsequent degradation to non-fluorescent products. Therefore,  
2-NBDG should allow the monitoring of cellular metabolic events. 
Accordingly, it was found that in Escherichia coli 2-NBDG accumulated in living cells and not in 
dead  cells  [37].  The  bacteria  could  be  readily  imaged  using  fluorescence  microscopy  with  UV 
illumination. A further, important validation was that 2-NBDG uptake was competitively inhibited by 
D-glucose and not by L-glucose (an enantiomer that rarely occurs in the natural world). This suggested 
that the bacterial glucose transport system was involved in 2-NBDG uptake. 
A rapid, follow-up study validated the intracellular fate of 2-NBDG [47]. In bacteria, 2-NBDG was 
shown to be phosphorylated after uptake, to produce fluorescent derivative (2-NBDG 6-phosphate), 
presumably by the glycolytic enzyme, hexokinase. 2-NBDG 6-phosphate was then converted back into 
2-NBDG by the enzyme glucose 6-phosphatase. 2-NBDG was then rapidly degraded to non-fluorescent 
products by the glycolytic pathway. The cellular breakdown of 2-NBDG is a useful property, because 
2-NBDG  signal  should  indicate  both  the  cellular  glucose  uptake  rate  and  metabolic  activity  [47], 
although  it  should  be  noted  that  2-NBDG  may  also  accumulate  as  glycogen  [48].  Indeed,  the 
usefulness and simplicity of 2-NBDG as a tracer for eukaryote cell viability was demonstrated in the 
same year [49]. Sensors 2012, 12  5010 
 
 
2.3. Increasing Use of 2-NBDG and 6-NBDG to Trace Glucose Transport in Different Biological Systems 
Following  the  development  of  2-NBDG,  there  has  been  an  increasing  number  of  research 
publications  utilizing  this  probe.  A  PubMed  search  (U.S.  National  Library  of  Medicine  National 
Institutes of Health) retrieved 77 publication for 2-NBDG after the year 1996, with 21 publications 
alone for the year 2011. Two important applications for 2-NBDG appear to account for much of this 
increased  use.  Firstly,  it  was  shown  that  2-NBDG  can  be  used  to  image  and  measure  signaling 
pathway-stimulated glucose uptake in single cells from the pancreas [36,38]. This was followed by a 
large number of publications using NBDG to validate novel anti-diabetic compounds with similar 
effects as the hormone insulin, i.e., the promotion of glucose uptake in insulin-sensitive cells, such as 
adipocytes and skeletal muscle cells (i.e., see [50–54]). Secondly, in cancer research, there has been 
increasing  focus  on  targeting  tumor  cell  metabolism  to  develop  cancer  drugs  (reviewed  in  
references [55–57]). This has stimulated the use of NBDG to monitor the increased glucose uptake in 
cancer cells (the Warburg effect, discussed in Section 1.1) [58]. For example, 2-NBDG has been used 
to develop high-throughput quantitative assays for glucose uptake in cancer cell lines [59] and as a 
method to monitor therapy response in breast cancer cell lines [60]. Importantly, potential clinical 
applications  for  2-NBDG  are  being  developed,  for  example  as  a  tracer  for  cisplatin  treatment  in 
ovarian  cancer  [61]  and  as  a  contrast  agent  for  detecting  of  Barrett's-associated  neoplasia  during 
confocal imaging [62]. A very interesting finding has been the demonstration that, in vivo, 2-NBDG 
imaging of murine tumors is possible by performing fluorescence colonoscopy [63]. In this study, 
NBDG-based imaging was compared and correlated with radioactive 2-deoxy-2 [18F]fluoro-D-glucose 
position  emission  tomography  (FDG-PET)  and  it  was  concluded  that  2-NBDG  is  an  optical  
analog of FDG-PET that can extend metabolic imaging to both minimally invasive and intra-operative 
settings [63]. 
2-NBDG use has also been extended to the study of brain cells, which, compared to other cell types, 
rely heavily on blood glucose for their energy supply (i.e., see [30,64,65]). In relation to these findings, 
another interesting recent report has shown that 2-NBDG can be used for localizing epileptic foci in an 
animal model, via injection into the tail vein [66]. Studies that show imaging of disease states in 
animals using 2-NBDG are important, because they can form the basis of subsequent studies which 
aim to replace the use of radioactive imaging agents in patients, such as FDG. 
Although 6-NBDG is less popular with the biological research community than 2-NBDG (in terms 
of published reports), it still continues to be utilized as a glucose tracer. For example, our own research 
group has used insulin-stimulated 6-NBDG uptake as a test for multipotent stem cell conversion into 
adipocyte  cells  [67,68].  Interestingly,  much  of  the  published  research  using  6-NBDG  has  been 
physiological studies of neurons and astrocytes (i.e., see [46,69,70]). In addition, 6-NBDG has been 
used to measure glial cell glucose transport in real-time using confocal microscopy cells [29]. Time 
resolution was an important consideration in this study because fluorescent techniques can resolve 
cellular events within seconds, whereas isotopic techniques can only resolve them within minutes. This 
is a critical issue for cells that change their metabolic status very rapidly, which occurs in brain tissue. 
Subsequent glucose utilization studies using 6-NBDG and 2-NBDG compared co-cultures of glial cells 
and neurons [30] and acute cerebellar slices [31], which are also not possible with glucose isotopes. 
Thus, fluorescent analogues are superior to isotope analogues in terms of temporal resolution and Sensors 2012, 12  5011 
 
 
spatial resolution. The stability of 6-NBDG in cells after cellular uptake, where it accumulates instead 
entering the glycolytic pathway, (which is the cellular fate of 2-NBDG), is a possible reason why  
6-NBDG is suitable for studying neuronal glucose transport. 
Nevertheless, issues remained concerning the use of NBDG glucose probes. For example, a major 
issue was the kinetic behavior of these tracers, which is not conventional when compared to cellular 
glucose uptake. It was shown that NBDG permeates the cell 50–100 times slower than glucose [44]. 
Moreover, other research groups have shown that glucose cannot compete effectively with NBDG 
uptake  [44,71].  For  example,  90%  inhibition  of  2-deoxyglucose  uptake  by  glucose  only  produces  
20–40% inhibition of 6-NBDG uptake [44]. This finding appears to be confusing if one considers that 
NBDG enters the cell more slowly than glucose and could indicate significant GLUT-independent 
uptake of NBDG. 
Fortunately, this issue was resolved in an important study from the laboratory of Professor Barros at 
the Centro de Estudios Cientí ficos, Chile [44]. This research group found that in astrocytes, 6-NBDG 
binds to GLUT1 with approximately 300 times higher affinity than glucose. This finding provided a 
valuable, parsimonious explanation for why 6-NBDG uptake is not efficiently displaced by glucose. In 
addition, this group also reported that, in light of this high affinity binding and low transport through 
GLUT,  when  compared  to  glucose,  exofacial  GLUT  inhibitors,  such  as  4,6-ethylidene-D-glucose, 
should  be  used  to  confirm  GLUT-specific  NBDG  uptake  (please  note  that  cytochalasin  B  is  an 
intracellular GLUT inhibitor). Although these results were obtained using 6-NBDG, the authors suggest 
that they can also explain the kinetics of 2-NBDG cellular uptake [44]. Further analysis of 6-NBDG 
uptake specificity investigated the temperature dependence of 6-NBDG uptake by astrocytes [72]. It 
was found that the temperature coefficient (Q10) of 6-NBDG uptake in astrocytes was similar to the 
Q10 of GLUT1 in  erythrocytes,  which was much higher than the  Q10 for simple  diffusion. This 
finding provides further evidence of a minor role for simple diffusion in 6-NBDG uptake. 
Our own research experience with 2-NBDG and 6-NBDG has also been positive. For example, we 
have confirmed that NBDG is transported into cells in an insulin-dependent manner (Figure 3). Thus, 
the use of NBDG as a relatively fast and convenient measure of glucose transport has greatly facilitated 
our work, which focuses on the discovery of new diabetes drug candidates. The non-radioactive nature 
of  NBDG  probes  has  allowed  us  to  develop rapid  screening  systems  to  discover  compounds  that 
induce glucose uptake, for subsequent analysis as anti-diabetic agents [53]. 
The proven usefulness of NBDG for diabetes, neurological and cancer research appears to be a 
factor  in  the  subsequent  development  of  alternative  fluorescent-tagged  glucose  bioprobes  by  the 
research community. In addition, diabetes and cancer are major diseases afflicting our society [73,74]. 
Thus, the development superior chemical probes to study these diseases are a priority for biomedical 
researchers. This is especially relevant for cancer research, because the NBDG probe could not replace 
the radioactive glucose tracer, FDG, as a tumor imaging agent in patients. These new advances in the 
development of fluorescent-tagged glucose bioprobes will be discussed in the following sections of 
this review. 
   Sensors 2012, 12  5012 
 
 
Figure 3. Data from our laboratory indicating that the fluorescent-tagged glucose probe,  
6-NBDG,  enters  cells  in  response  to  insulin  treatment.  Two  populations  of  cells  were 
cultured  together;  fibroblasts  and  adipocytes,  which  can  be  distinguished  under  DIC 
microscopy by adipocyte-specific deposition of lipid droplets. (A) Adipocytes are insulin 
sensitive cells, unlike fibroblasts. In response to insulin treatment, adipocytes selectively 
take-up the NBDG probe (as shown by FITC fluorescence microscopy); (B) However, 
NBDG treatment without insulin produced markedly less NBDG uptake by the adipocytes; 
(C,D)  Two  new  triazine-based  insulin  mimetic  agents  (termed  AP-III-a4  and  AP-I-h7) 
could  also  induce  NBDG  uptake  selectively  in  adipocytes,  suggesting  that  these 
compounds are attractive candidates for further development as diabetes drugs. Reference: 
MolBiosyst. 2011, Feb;7(2):346–358; reproduced with permission from the author). 
 
3. Fluorescent-Tagged Glucose Bioprobes Developed Since the Year 2000 
3.1. Pyropheophorbide 2-deoxyglucosamide (Pyro-2DG) 
Pyro-2DG  was  developed  in  2003  by  Gang  Zheng‟s  research  group  at  the  University  of 
Pennsylvania  (Figure  4(A))  [75].  Pyro-2DG  was  synthesized  because  2-NBDG  internalization  in 
cancer cells had demonstrated that glucose-tagged probes larger than FDG can accumulate into tumors, 
in both a GLUT and hexokinase-dependent manner. 
The development of Pyro-2DG marked the initiation of alternative chemical fluorescent groups for 
glucose attachment. Pyro-2DG contains a near-infrared (NIR) dye conjugate. NIR dyes had produced 
considerable research interest, because in addition to  their use as a fluorescence probe for cancer 
detection, the NIR dye could also photo-sensitize cancer cells for treatment by photodynamic therapy 
(PDT) [76]. This was tested in rats that had undergone glioma tumor cell transplantation. Pyro-2DG 
was delivered to the tail vein of the anaesthetized rats and 30 minutes later the tumor cell graft was 
subjected  to  PDT.  The  tumors  were  then  excised  and  imaged  with  a  low-temperature  scanning 
fluorometer. This confirmed that Pyro-2DG had localized to the tumors and induced noticeable tumor 
destruction after PDT. 
FITC DIC Fibroblast
Fibroblast
Adipocyte
Fibroblast
Adipocyte
FITC DIC
C) 6-NBDG uptake: Compound AP-III-a4
A) 6-NBDG uptake: Insulin
FITC DIC
B) 6-NBDG uptake: NBDG alone
Bar = 40 µm
D) 6-NBDG uptake: Compound AP-I-h7
FITC DIC
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AdipocyteSensors 2012, 12  5013 
 
 
Figure 4. (A) Chemical structure of pyropheophorbide 2-deoxyglucosamide (Pyro-2DG), 
developed  in  2003  by  Gang  Zheng  at  the  University  of  Pennsylvania;  
(B)  Chemical  structure  of  Cy5.5-D-glucosamine  (Cy5.5-2DG),  developed  in  2006  by 
Sanjiv Sam Gambhir at Stanford University. 
 
 
(A)  (B) 
This same research group rapidly published a follow-up study that assessed the effectiveness of 
Pyro-2DG as a fluorescent metabolic index for tumors [77]. Rat or mouse cancer models received 
Pyro-2DG via tail vein injection. The tumors were then surgically excised and subjected to fluorescent 
imaging and histopathological evaluation. In addition, flattened tumor surfaces were analyzed with a 
bifurcated optical fiber bundle to measure the PN/(Fp+PN) redox ratio (where PN denotes reduced 
pyridine nucleotides and Fp denotes oxidized flavoproteins), which is an index for measuring cell 
metabolism  and  is  relatively  high  in  tumors  compared  to  healthy  tissues.  For  both  cancer animal 
models, it was found that Pyro-2DG selectively accumulated in the tumor models compared to the 
surrounding normal tissues at a ratio of approximately 10:1. Interestingly, there was also a high degree 
of correlation between the PN/(Fp+PN) redox ratio and Pyro-2DG uptake. This indicates that Pyro-2DG 
could be employed as an extrinsic NIR fluorescent metabolic index tracer for tumor tissue, which 
would allow the monitoring of metabolic responses after treatment with cancer drugs. However, in 
spite of these advantages, Pyro-2DG has not been utilized by the research community and there is no 
subsequent  published  report  concerning  this  probe.  This  may  be  due  to  Pyro-2DG  not  being 
commercialized, which restricts its availability for researchers. 
3.2. Cy5.5-D-glucosamine (Cy5.5-2DG) 
Cy5.5-2DG was developed in by Sanjiv Sam Gambhir at Stanford University in 2006 [78]. The 
chemical structure of Cy5.5-2DG is shown in Figure 4(B). Like Pyro-2DG, Cy5.5-2DG is a NIR 
fluorescent glucose analogue synthesized for imaging tumor metabolism in living subjects. Tumor 
targeting of Cy5.5-2DG was assessed in two rodent subcutaneous tumor graft models and imaged 
using the XenogenIVIS 200 small animal fluorescent imaging system. Tumor localization was clearly 
visualized in living mice 30 minutes after tail vein delivery of Cy5.5-2DG. The tumor tissue:healthy 
O
OH
OH O H
O H
N H O
N
H
N
NH N
O
 
   
 
 
N
+
N
 
   
   
SO3
-
SO3
-
SO3
-
O3
-
S
O
OH
OH O H
N H
O
O HSensors 2012, 12  5014 
 
 
tissue  image  contrast  ratio  could  approach  3:1,  which  compares  favorably  with  a  micropositron 
emission tomography imaging of 4:1 for FDG [78]. However, Cy5.5-2DG uptake in tumor cells could 
not be inhibited by a relatively high extracellular glucose concentration, which suggests that neither 
GLUT  or  the  hexokinase  pathway  regulate  Cy5.5-2DG  uptake,  unlike  2-NBDG.  Nevertheless,  
Cy5.5-2DG has greater stability in the mouse model (4 days post injection) compared to 2-NBDG. 
While Cy5.5-2DG can be useful in labeling cancer cells for cell trafficking and in vivo staining of 
tumors by its high specificity, it is not clear how Cy5.5-2DG localizes and is retained in tumor. This 
finding emphasizes the importance of fluorescent dye size when preparing fluorescent tagged-glucose 
analogues. Since the year 2006, there has been no published scientific report concerning this probe, 
despite its ability to localize in tumor tissue. 
3.3. Cy3-Linked O-1-glycosylatedglucose (Cy3-α-glucose and Cy3-β-glucose) 
The synthesis of both anomers (α and β) of Cy3-labeled D-glucose was reported in 2007, by the 
research group of Park at Seoul National University, Korea [71]. The chemical structures of Cy3-α-
glucose  and  Cy3-β-glucose  are  shown  in  Figure  5.  The  Cy3  fluorescent  dye  was  chosen  for 
conjugation because of its compatibility with biological systems and tolerance to intense light sources, 
compared to the fluorescent group of 2-NBDG. 
Figure 5. (A,B) Chemical structures of Cy3-linked O-1-glycosylatedglucose (Cy3-α-glucose 
(A) and Cy3--glucose (B)) developed by Park at Seoul National University. 
 
(A) 
 
(B) 
Importantly, Cy3-Glc-α labeled cancer cells more intensely than 2-NBDG (to achieve 80% of the 
Cy3-Glc-α signal, a 10-fold increase in 2-NBDG concentration and a 20-fold increase in fluorescence 
microscopy exposure time was required). Due to this relatively strong detection, Cy3-Glc-α could be 
applicable for bioassays without requiring glucose starvation. However, although the Cy3-Glc-α has 
superior  imaging  merits  compared  to  2-NBDG,  it  has  not  yet  been  tested  in  an  animal  tumor  
model. Cy3-conjugated glucose probes would be further developed in follow-up study (discussed in  
Section 4.2). 
   
O
O H
O H
O
OH
N N
O
NH
O
O
NH
O
O H
O H
OH
O
N N
O
NH
O
O
NHSensors 2012, 12  5015 
 
 
3.4. IRDye 800CW 2-DG 
IRDye  800CW  2-DG  is  a  NIR  fluorescent-conjugated  glucose  analogue  developed  in  2009  by  
LI-COR Biosciences, Inc. [79]. Unfortunately, to our knowledge the precise chemical structure has not 
been disclosed. Uptake of IRDye 800CW 2-DG in carcinoma cells was shown to be dependent on 
GLUT, because high extracellular glucose or a GLUT antibody inhibited probe uptake. Intravenous 
delivery of IRDye 800CW 2-DG in 4–6 weeks old mouse cancer models also demonstrated localization 
to the tumor tissue within 24 h, as visualized by the Pearl
TM small animal imaging system [79]. A rapid 
follow-up study in 2009, from the University of Texas Southwestern Medical Center, also demonstrated 
the usefulness of IRDye 800CW 2-DG [80]. Probe localization to an intracranial tumor mouse model 
was  monitored  longitudinally  by  in  vivo  fluorescence  imaging  after  tail  vein  delivery.  There  was 
significantly higher signal intensity from IRDye 800CW 2-DG in the tumor side of the brain than the 
contralateral hemisphere, 24 h after injection (tumor tissue/normal tissue signal ratio (TNR = 2.860.7), 
which was increased after removal of the scalp (TNR = 3.761.1) and skull (TNR = 4.261.1) (Figure 6). 
Thus, these very promising results suggest that IRDye 800CW 2-DG may serve as a useful probe for 
noninvasive tumor assessment in preclinical animal models. To date, these are the only published 
studies describing IRDye 800CW 2-DG and we eagerly await subsequent research papers describing 
this probe. 
Figure 6. Imaging IRDye 800CW 2-DG uptake in a mouse model of intracranial glioma. 
For the first four hours, there was no obvious contrast between the tumor side of the brain 
and the normal brain. However, after 24 h later, signal remained only in the tumor side of 
the brain. Higher contrast was seen after scalp retraction or removal of the skull. Image 
reproduced from PLoS One; 2009, Nov 30;4(11):e8051. 
 
3.5. Development of Two-Photon Glucose Tracers 
Two-photon  excitation  microscopy  (TPM)  allows  the  fluorescent  imaging  of  living  tissue  at  a 
relatively high depth (up to 1 mm) [81]. Both 2-NBDG and 6-NBDG have been utilized for two 
photon microscopy of brain slices [31]. In addition, two photon microscopy has been used to image  Sensors 2012, 12  5016 
 
 
6-NBDG uptake in brain tissue in vivo [46]. Two-photon glucose analogues were developed in 2009, 
from the laboratory of Park at Seoul National University (Figure 7) [82]. Development of novel TPM 
glucose  bioprobes  should  address  a  number  of  parameters,  including  sufficient  water  solubility, 
preferential probe uptake by cancer cells due to enhanced glycolysis and a large two photon cross-
section for generating a bright TPM image [82]. The chemical strategy adopted was to link glucose to 
acedan,  which  is  a  polarity-sensitive  fluorophore  that  has  been  successfully  employed  in  the 
development of TPM probes [83,84]. 
Figure 7. Chemical structures of the two-photon glucose analogues, AG1 (A) and AG2 (B), 
developed for two photon microscopy in 2009 by Park at Seoul National University. 
 
(A) 
 
(B) 
An important demonstration was that AG2 is taken up by cellular GLUT. In addition, AG2 uptake 
by tumor cells is decreased by cancer drugs, such as taxol. Moreover, TPM could produce a much 
brighter image for AG1 and AG2, compared to the probes 2-NBDG or Cy3-α-glucose. Additional tests 
showed preferential AG2 uptake in colon cancer biopsies, which was dependent on drug treatment, i.e., 
patients receiving an anti-cancer drug showed reduced AG2 uptake in the cancer biopsy. AG2 uptake 
can also be monitored at a tissue depth of around 1 mm [85,86]. Thus, AG2 may be become useful in 
the development of customized cancer therapy for a patient, via comparison of AG2 uptake rates in 
healthy versus tumor tissue. 
4. Recent Developments in Fluorescent Tagged Glucose Bioprobe Development (Since 2010) 
Although a number of advances have been achieved in the synthesis of glucose tagged bioprobes,  
2-NBDG  and  6-NBDG  remain  the  most  popular  choice  for  fluorescent-based  analysis  of  glucose 
uptake in biological systems (in terms of published research papers on PubMed, US National Library 
of Medicine National Institutes of Health, from 2010–2011). NBDG probes remain the most popular 
choice because they are commercially available, relatively cheap to purchase and have been already 
characterized in several research publications. However, there was still no fluorescent-tagged glucose 
probe that could replace FDG for visualizing tumors in cancer patients. Consequently, in the past two 
years,  a  number  of  new  fluorescent  tagged  glucose  bioprobes  have  been  developed.  These  latest 
research advances are discussed in the remainder of this review. 
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4.1. Development of CyNE 2-DG 
The NIR fluorescent deoxyglucose analogue, CyNE 2-DG, was synthesized by the laboratory of 
Professor  Young-Tae  Chang  at  the  National  University  of  Singapore  (Figure  8(A))  [87].  The 
performance of CyNE 2-DG was directly compared with IRDye 800CW 2-DG, with the demonstration 
that CyNE 2-DG produced significantly higher fluorescence signal after incubation in cancer cells. It 
was speculated that this difference is due to the more negatively charged chemical structure of IR Dye 
800CW  2-DG,  which  would  decrease  cell  membrane  permeability.  Importantly,  high  extracellular 
glucose could dose dependently reduce CyNE 2-DG uptake in cancer cells, indicating that cellular 
GLUT regulates probe uptake. However, it should be noted that tumor labeling by CyNE 2-DG was 
not tested in an animal cancer model. 
Figure 8. (A) Chemical structure of CyNE 2-DG, developed by Chang at the National 
University of Singapore; (B) Chemical structure of GB2-Cy3, developed by Park at Seoul 
National University. 
   
(A)  (B) 
4.2. Next Generation of Cy3-Labeled Glucose Probes 
As  a  follow-up  to  their  study  in  2007,  the  laboratory  of  Park  at  Seoul  National  University 
synthesized seven new Cy3-labeled glucose probes [88]. The aim of this approach was to produce a 
Cy3-labeled glucose probe that would be applicable to the monitoring of glucose utilization in diabetes 
drug screening. The best probe from these seven was selected on the basis of glucose-dependent probe 
uptake in fibroblast cells. The probe GB2-Cy3 (Figure 8(B)) was found to produce the best fluorescent 
signal  in  the  cells,  which  was  also  inhibited  dose  dependently  by  competition  with  extracellular 
glucose. In fact, this competition by extracellular glucose was greater than that measured for 2-NBDG. 
The  performance  of  GB2-Cy3  was  monitored  in  insulin-sensitive  muscle  cells,  because  novel  
anti-diabetic drug candidates should be able to mimic the effects of insulin [53]. GB2-Cy3 cellular 
uptake increased after insulin treatment and this could be blocked by wortmannin, which is a well-
known insulin pathway inhibitor [89]. Importantly, GB2-Cy3 uptake can be measured in real-time 
using  confocal  laser  scanning  microscopy.  Thus,  GB2-Cy3  has  the  potential  to  become  a  useful 
glucose probe for diabetes drug screening research. This work is also of interest, because much of the 
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other  current  research  for  glucose  probe  development  is  aimed  at  cancer  applications,  rather than 
diabetes. 
4.3. Luminescent Rhenium(I) Polypyridine Glucose Conjugates 
Luminescent  transition-metals  have  also  been  recently  investigated  as  tools  to  monitor  cellular 
glucose uptake [90]. The laboratory of Kenneth Kam-Wing Lo, at the University of Hong Kong, has 
recently  developed  three  rhenium(I)  polypyridine  glucose  complexes  and  assessed  their  uptake  in 
cancer cells. The chemical structure of the best performing complex (complex 3) is shown in Figure 9, 
as determined by both relative signal intensity and cellular uptake rates. Complex 3 performed well in 
cellular  assays,  showing  uptake  that  was  dependent  on  extracellular  glucose  concentration  and 
decreased uptake in cancer cells treated with the cancer drug, taxol [91]. Interestingly, complex 3 was 
shown to accumulate in the cell mitochondria. This could also be an encouraging feature for this probe, 
because  the  glycolysis  enzyme,  hexokinase  (that  phosphorylates  glucose),  is  localized  at  the 
mitochondria [92]. Another positive feature of the probe is photostability. Excitation for 150 seconds 
produced 30% decreased intensity, compared to a 90% reduction for 2-NBDG. Thus, this may become 
a promising probe for monitoring glucose uptake in cancer, although animal studies still need to be 
undertaken. 
Figure  9.  Chemical  structure  of  the  pyridine4,7-diphenyl-1,10-phenanthroline  
(Ph2-phen)rhenium(I)  polypyridine  glucose  complex,  developed  by  the  laboratory  of 
Professor Kenneth Kam-Wing Lo at the University of Hong Kong. 
 
4.4. A New Two Photon Tracer: Star-Shaped Glycosylated Conjugated Oligomer 
A  star-shaped  glycosylated  conjugated  oligomer,  TFBS,  has  recently  been  developed  by  the 
laboratory  of  Bin  Liu  at  the  National  University  of  Singapore  (Figure  10)  [93].  TFBS  is  a  NIR 
multibranched octupolar chromophore, which was designed to maximize the cross section that can be 
imaged by TPM. TFBS is also water soluble, unlike other related chromophores with relatively high 
cross  section  values,  making  TFBS  suitable  for  biological  applications.  The  TFBS  probe  has  a 
significantly  larger  molecular  weight,  relative  to  the  other  fluorescent-tagged  glucose  bioprobes 
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described  in  this  review.  However,  cellular  uptake  of  TFBS  was  shown  to  be  dependent  on  the 
presence of the glucose groups. This led the authors of this study to conclude that glucose transporters 
may have a role in TFBS uptake. However, further validation experiments, such as competition of 
cellular uptake by extracellular glucose or uptake inhibition by GLUT inhibitors, was not performed in 
this study. So far, TFBS has only been tested in cancer cells; staining of patient tumor biopsies was not 
assessed. Nevertheless, the cross sectional range for TFBS in stained cancer cells was higher than the 
majority of reported two-photon fluorescence probes designed for cellular imaging [93]. 
Figure  10.  Chemical  structure  of  the  star-shaped  glycosylated  conjugated  oligomer, 
fluorescent-tagged  glucose  bioprobe,  TFBS  (4,4‟,4‟‟-tris(4-(2-(4-(benzo-[d]thiazol-2-
yl)phenyl)-9,9‟-bis(6-thiol-β-D-glucose)-hexyl)-fluoren-7-yl)phenylamine),  developed  by 
the laboratory of Bin Liu at the National University of Singapore. 
 
5. Conclusions 
The  development  of  novel  fluorescent-tagged  glucose  bioprobes  is  a  priority  for  biomedical 
research. Altered glucose metabolism is a fundamental aspect of cancer and diabetes [3,94]. It has been 
16 years since the development of the glucose probe, 2-NBDG, but, in terms of published scientific 
papers per year, this probe still remains the most popular choice for laboratory researchers. Moreover, 
basic  research  publications  using  glucose  radioisotopes,  such  as  2-deoxyglucose,  still  outnumber 
publications  that  use  NBDG.  However,  research  publications  that  use  fluorescent-tagged  glucose 
bioprobes are increasing each year (Figure 11), which may be due to increasing awareness among 
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scientists that fluorescent probes can offer substantial advantages, such as superior spatial resolution 
for imaging and avoidance of logistical problems associated with using radioactivity in the laboratory.  
Figure 11. Histogram comparing research publications for 2-NBDG and 6-NBDG since 
the year 2005, according to PubMed (US National Library of Medicine National Institutes 
of Health). However, it should be noted that in 2011, there were 1,740 publications that 
used 2-deoxyglucose.  
 
This is an exciting time for the development of fluorescent-tagged glucose bioprobes, because an 
increasing number of novel probes are being reported each year. In addition, a number of these possess 
features that are superior to NBDG. Especially, new probes that utilize NIR appear to be promising for 
biomedical  applications  because  they  can  be  utilized  for  live  imaging  and  are  now  commercially 
available [80]. Advances in microscopy, such as the rapid development of TPM is also being exploited 
by researchers [82,93] and it can be envisaged that these new TPM-optimized glucose bioprobes will 
soon become commercially available. Moreover, the new Cy3-labeled glucose probes also possess a 
number  of  advantages  compared  to  NBDG  [71,88].  Individual  features  of  the  currently  reported 
fluorescent-tagged glucose bioprobes are shown in Table 1. The personal opinions of the authors of 
this review is that it will only be a few years before a fluorescent-tagged glucose bioprobe will be 
developed that can replace the current reliance on radioisotopes to visualize glucose uptake in the 
clinical setting. 
Table 1. A comparison of current fluorescent-tagged glucose bioprobes.  
Probe and Year 
Developed 
Molecular 
Weight 
Commercial 
Availability 
Research 
Application 
Wavelength 
(nm) 
Cell Types 
Tested 
Competition 
with D-glucose 
Tested in 
Animals 
6-NBDG (1985)  342.26 
Invitrogen, 
Corp. 
Diabetes, 
Cancer, 
Neurology 
Ex 470 
Em 538 
Multiple cell types 
from various tissues 
Yes  Mouse & Rat 
2-NBDG (1996)  342.26 
Multiple 
companies 
Diabetes, 
Cancer 
Neurology 
Ex 475 
Em 550 
Multiple cell types 
from various tissues 
Yes 
Mammalian, 
fish, 
invertebrates 
Pyro-2DG 2.3 
(2003) 
681.77  No  Cancer 
Ex 665 
Em 720 
Rat glioma  Yes  Rat 
Cy5.5-2DG 
(2006) 
1077.20  No  Cancer 
Ex 675 
Em 695 
Melanoma, glioma 
and carcinoma 
No  Mouse Sensors 2012, 12  5021 
 
 
Table 1. Cont. 
Cy3-labeled α-
glucose (2007) 
734.92  No  Cancer 
Ex 545 
Em 555 
Fibroblasts and 
carcinoma cells 
Yes  No 
IRDye 800CW 
2-DG (2009) 
Not 
published 
LI-COR 
Biosciences 
Cancer 
Ex 774 
Em791 
Fibroblasts, 
melanoma and 
carcinoma 
Yes  Mouse 
AG2 (2009)  501.57  No  Cancer 
Ex 780 
Em 520-620 
Embryonic kidney, 
embryonic fibroblast 
and carcinoma 
Yes  No 
CyNE 2-DG 
(2011) 
970.71  No  Cancer 
Ex 740 
Em 815 
Carcinoma  Yes  No 
GB2-Cy3 (2011)  717.91  No  Diabetes 
Ex 488 
Em 564-606 
Fibroblast and 
myoblast 
Yes  No 
Phen complex 
(2011) 
1168.33  No  Cancer 
Ex 405 (Em 
not stated) 
Carcinoma  Yes  No 
TFBS (2011)  2951.75  No  Cancer 
Ex 800 
Em 500-600 
Carcinoma  No  No 
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